Content about Lansoprazole

April 4, 2013
Allergy Relief 2013

The March/April 2013 Allergy Relief Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Claritin-D, Allegra-D, Zyrtec-D, Benadryl-D, Advil Allergy and Congestion Relief, UrgentRx Allergy Attack, Hyland's Seasonal Allergy Relief, Similasan's Nasal Allergy Relief and Boiron's Sabadil.

The March/April 2013 Allergy Relief Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Claritin-D, Allegra-D, Zyrtec-D, Benadryl-D, Advil Allergy and Congestion Relief, UrgentRx Allergy Attack, Hyland's Seasonal Allergy Relief, Similasan's Nasal Allergy Relief and Boiron's Sabadil.

January 28, 2013
Vitamins & Supplements 2013

The January/February 2013 Vitamins & Supplements Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Centrum, One-A-Day, NatureMade, VitaFusion, Alive, VirMax-T, MoveFree, Bioglan and Voots products.

The January/February 2013 Vitamins & Supplements Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Centrum, One-A-Day, NatureMade, VitaFusion, Alive, VirMax-T, MoveFree, Bioglan and Voots products.

Click here for the complete guide.

November 28, 2012
Cough, cold and flu

The November/December 2012 Cough, Cold and Flu Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Mucinex, Vicks, Advil, Theraflu, Delsym, St. Joseph, Hyland's Similasan and Zicam products.

The November/December 2012 Cough, Cold and Flu Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Mucinex, Vicks, Advil, Theraflu, Delsym, St. Joseph, Hyland's Similasan and Zicam products.

Click here for the complete guide.

October 4, 2012
Digestive Aids

The September/October 2012 Digestive Aids Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Tums, Di-Gel, Zantac, Pepcid AC, Prilosec OTC, Prevacid 24HR, Dulcolax, Senokot and Pepto-Bismol.

The September/October 2012 Digestive Aids Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Tums, Di-Gel, Zantac, Pepcid AC, Prilosec OTC, Prevacid 24HR, Dulcolax, Senokot and Pepto-Bismol.

Click here for the complete guide.

September 17, 2012
FDA approves Wockhardt generic ulcer drug

The Food and Drug Administration has approved a generic ulcer treatment made by Wockhardt, the Indian drug maker said Monday.

PARSIPPANY, N.J. — The Food and Drug Administration has approved a generic ulcer treatment made by Wockhardt, the Indian drug maker said Monday.

Wockhardt announced the approval and launch of lansoprazole delayed-release capsules in the 15-mg and 30-mg strengths. The drug is a generic version of Prevacid, which Takeda markets in the United States.

The drug has a market of about $700 million in the United States, according to IMS Health.

August 17, 2012
Generics contend in PPIs

Procter & Gamble’s Prilosec OTC still is the best-selling antacid on the market, with more than $252.7 million in annual sales for the 52 weeks ended July 8 across food, drug and mass (excluding Walmart), followed by fellow proton-pump inhibitor Novartis’ Prevacid 24HR ($104.1 million).


Procter & Gamble’s Prilosec OTC still is the best-selling antacid on the market, with more than $252.7 million in annual sales for the 52 weeks ended July 8 across food, drug and mass (excluding Walmart), followed by fellow proton-pump inhibitor Novartis’ Prevacid 24HR ($104.1 million).


Both of those antacid heavy hitters are losing dollar share to their generic-
equivalent competitors, however, leaving GlaxoSmithKline’s venerable Tums brand as the largest growth brand within antacids ($91.3 million in sales, up 2.5%).


May 21, 2012
Dr. Reddy's launches heartburn treatment

Dr. Reddy's Labs has launched a generic version of a popular over-the-counter drug for treating heartburn, the company said Monday.

HYDERABAD, India — Dr. Reddy's Labs has launched a generic version of a popular over-the-counter drug for treating heartburn, the company said Monday.

Dr. Reddy's announced the launch of lansoprazole delayed-release capsules in the 15-mg strength in pack sizes of 14, 28 and 42. The drug is a generic version of Novartis Consumer Health's Prevacid 24 HR capsule brand, which had sales of $115 million during the 12-month period ended in March, according to SymphonyIRI InfoScan Reviews.

May 18, 2012
Perrigo launches store-brand Prevacid 24HR

Perrigo on Friday announced that it has received final approval from the Food and Drug Administration for its abbreviated new drug application for lansoprazole capsules in the 15-mg strength.

ALLEGAN, Mich. — Perrigo on Friday announced that it has received final approval from the Food and Drug Administration for its abbreviated new drug application for lansoprazole capsules in the 15-mg strength. The capsules are a generic equivalent of Novartis' Prevacid 24HR capsules.

Sales for Prevacid OTC were approximately $220 million, Perrigo reported.

Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

April 23, 2012
Par buys rights to generic drug for GERD

Par Pharmaceutical has bought rights to a generic drug for gastroesophageal reflux disease from Handa Pharmaceuticals, Par said.

WOODCLIFF LAKE, N.J. — Par Pharmaceutical has bought rights to a generic drug for gastroesophageal reflux disease from Handa Pharmaceuticals, Par said.

Handa, based in Fremont, Calif., sold rights to the regulatory approval application it filed with the Food and Drug Administration for dexlansoprazole capsules, a generic version of Takeda's Dexilant, in the 60-mg strength.

October 11, 2011
Antacids expect some upset

Sales of antacid tablets are up almost 3%. And while nobody is suggesting that upward trajectory is going to change anytime soon, there will be a decent amount of volatility in the coming year.


Sales of antacid tablets are up almost 3%. And while nobody is suggesting that upward trajectory is going to change anytime soon, there will be a decent amount of volatility in the coming year.


August 17, 2011
Perrigo 2012 targets: Prevacid 24HR and Align; Lipitor on the horizon?

Perrigo is planning to launch more than 45 new products in fiscal 2012 that will translate into approximately $190 million added to annual Perrigo sales, Perrigo chairman, president and CEO Joe Papa told analysts during the company's fourth-quarter conference call Tuesday.

ALLEGAN, Mich. — Perrigo is planning to launch more than 45 new products in fiscal 2012 that will translate into approximately $190 million added to annual Perrigo sales, Perrigo chairman, president and CEO Joe Papa told analysts during the company's fourth-quarter conference call Tuesday.

And while none of these new over-the-counter private-label products will help reduce cholesterol levels, Papa did set the stage for a future store-brand equivalent to Pfizer's blockbuster statin Lipitor.

August 8, 2011
Digestive Aids

Breaking down OTC digestive aids by indication, active ingredients, purpose and dosage.

The fall 2011 Digestive Aids Ingredient Guide breaks down the indication, active ingredients, purpose and dosage of such OTC digestive aids as Tums Ultra, Alka-Seltzer, Zantac, Pepcid AC, Prilosec OTC, Prevacid 24-HR, Dulcolax, MiraLax, Imodium A-D, Pepto-Bismol, Align and Culturelle.

Click here for the complete guide.

June 20, 2011
Three’s not a crowd: Top antacids hold their own


Good things come in three — like the three antacids that for the 52 weeks ended April 17 collectively generated more than $118 million in sales on top of the sales base they had established in the year-ago period.



Good things come in three — like the three antacids that for the 52 weeks ended April 17 collectively generated more than $118 million in sales on top of the sales base they had established in the year-ago period.


April 18, 2011
Study: Drug-drug interaction warning letters work

A letter educating healthcare providers regarding a drug-drug interaction between prescription anticlotting drug Plavix (clopidogrel) and a proton-pump inhibitor has resulted in a reduction in the number of patients combining the two therapies, according to a new study by Prime Therapeutics released Monday.

ST. PAUL, Minn. — A letter educating healthcare providers regarding a drug-drug interaction between prescription anticlotting drug Plavix (clopidogrel) and a proton-pump inhibitor has resulted in a reduction in the number of patients combining the two therapies, according to a new study by Prime Therapeutics released Monday.

April 5, 2011
Takeda tries to block Impax's launch of generic Dexilant

Generic drug maker Impax Labs is hoping to become the first to market a version of a gastroesophageal reflux disease treatment made by Takeda Pharmaceutical.

HAYWARD, Calif. — Generic drug maker Impax Labs is hoping to become the first to market a version of a gastroesophageal reflux disease treatment made by Takeda Pharmaceutical.

Impax said Tuesday that it had filed an approval application with the Food and Drug Administration for dexlansoprazole delayed-release capsules in the 30-mg and 60-mg strengths. The drug is a version of Takeda’s Dexilant.

April 5, 2011
Takeda: Dexilant, Prevacid have less inhibiting effects on Plavix's efficacy than counterparts

Studies have indicated that proton-pump inhibitors, used for treating gastroesophageal reflux disease, reduce the efficacy of a popular blood-thinning drug, but Takeda Pharmaceuticals North America announced on Tuesday the results of a new study indicating that its own PPIs may have less of an effect.

NEW ORLEANS — Studies have indicated that proton-pump inhibitors, used for treating gastroesophageal reflux disease, reduce the efficacy of a popular blood-thinning drug, but Takeda Pharmaceuticals North America announced on Tuesday the results of a new study indicating that its own PPIs may have less of an effect.

December 22, 2010
Prilosec OTC’s ‘Heartburn gone … power on’ tagline nixed by NAD

The National Advertising Division of the Council of Better Business Bureaus on Tuesday ruled that Procter & Gamble provided reasonable support for claims that Prilosec OTC provides “superior acid control” over a competing product, Prevacid 24HR. However, the NAD recommended P&G discontinue a comparative claim made in a context that doesn’t reference acid control, the review board added.

NEW YORK — The National Advertising Division of the Council of Better Business Bureaus on Tuesday ruled that Procter & Gamble provided reasonable support for claims that Prilosec OTC provides “superior acid control” over a competing product, Prevacid 24HR. However, the NAD recommended P&G discontinue a comparative claim made in a context that doesn’t reference acid control, the review board added.

P&G’s Prilosec OTC claims were challenged by Novartis Consumer Health, maker of Prevacid 24HR. Claims at issue included:

December 7, 2010
P&G, GSK hold their own 
in crowded antacid aisle

NEW YORK — Last year, the big question on every­one’s mind was: How many brands can actually thrive in what has become a cluttered antacid shelf? Because just exactly how many heartburn sufferers are there?


November 15, 2010
Takeda launches GetToKnowGERD.com

Drug maker Takeda Pharmaceuticals is launching a campaign to raise awareness of gastroesophageal reflux disease,...

NEW YORK — Drug maker Takeda Pharmaceuticals is launching a campaign to raise awareness of gastroesophageal reflux disease, the company said Tuesday.

 

Takeda created the website GetToKnowGERD.com to coincide with GERD Awareness Week, which takes place from Nov. 21 to 27. The company also is using the occasion to promote the GERD drug Dexilant (dexlansoprazole).

 

 

November 14, 2010
Reporters Notebook

K-V Pharmaceutical has created a new marketing subsidiary for generic drugs, the company said. K-V...

October 18, 2010
Dr. Reddy's to launch generic Prevacid

Dr. Reddy's disclosed on Tuesday it will market a generic peptic ulcer treatment....

HYDERABAD, India Dr. Reddy's disclosed on Tuesday it will market a generic peptic ulcer treatment.

Dr. Reddy's lansoprazole delayed-release capsules will be available in 15-mg and 30-mg strengths, the drug maker said. The capsules are the generic version of Takeda's Prevacid delayed-release capsules.

The FDA approved Dr. Reddy’s abbreviated new drug application for the drug on Oct. 15.

October 17, 2010
Teva, Sandoz launch Prevacid SoluTab generics

The Food and Drug Administration granted approval for Teva's abbreviated new drug application to market...

JERUSALEM The Food and Drug Administration granted approval for Teva's abbreviated new drug application to market a generic version of a drug designed to treat peptic ulcers.

The generic drug maker said that its drug, lansoprazole, is a generic version of Takeda’s Prevacid SoluTab. Annual sales of the branded product were approximately $453 million in the United States, according to IMS sales data.

Sandoz, the generics division of Swiss drug maker Novartis, also announced the launch of its own version of Prevacid SoluTab.

October 14, 2010
Innovations necessary to achieve better health outcomes

During the Academy of Managed Care Pharmacy 2010 Educational Conference held Oct. 13 to 15,...

WHAT IT MEANS AND WHY IT'S IMPORTANT During the Academy of Managed Care Pharmacy 2010 Educational Conference held Oct. 13 to 15, CVS Caremark shared data to further demonstrate ways to curb drug costs. This is important because what these studies, and others like it, continue to illustrate is that there are a variety of ways to reduce prescription drug costs beyond simply cutting prices to levels that could compromise a pharmacy's ability to deliver the high-quality service necessary to achieve better health outcomes.

August 12, 2010
FDA's new video addresses fracture risk when using PPIs

The Food and Drug Administration on Aug. 9 posted a video outlining the revised prescription...

SILVER SPRING, Md. The Food and Drug Administration on Aug. 9 posted a video outlining the revised prescription and over-the-counter labels for proton-pump inhibitors that include new safety information about a possible increased risk of fractures of the hip, wrist and spine with the use of these medications.

 

The video is a part of the FDA’s Drug Info Rounds, “a program by pharmacists for pharmacists,” and presented by the Division of Drug Information pharmacists division of FDA.

 

 

June 6, 2010
Marketing pieces of the digestive puzzle

When Schering-Plough Consumer Healthcare began distributing its Zegerid OTC in April, the last piece of...